PCSK9 and ischemic stroke: The landmark FOURIER trial showed that PCSK9‐i not only achieve profound LDL‐C reduction (median LDL‐C <25 mg/dL) but also confer robust cardiovascular benefits, including a 15% reduction in cardiovascular mortality and a 21% lower risk of ischemic stroke.